Home › Compare › IGPPF vs ABBV
IGPPF yields 15.46% · ABBV yields 3.06%● Live data
📍 IGPPF pulled ahead of the other in Year 1
Combined, IGPPF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IGPPF + ABBV for your $10,000?
Impellam Group plc provides staffing solutions, human capital management, and outsourced people-related services in the United Kingdom, North America, rest of Europe, and Australasia. It operates through four segments: Global Managed Services, STEM, Regional Specialist Staffing, and Healthcare. The Global Managed Services segment engages in the design, implement, coordinate, and report on the talent acquisition process through the provision of multi-disciplinary outsourced recruitment services under the Comensura, Guidant Global, and Flexy brand names. The STEM provides specialist contract and permanent recruitment services of scientists, clinicians, engineers, IT, and digital specialists under the Lorien, Carbon60, Bartech, and SRG brand names. The Regional Specialist Staffing segment offers staffing services for warehouse workers, secretaries, call centre operatives, lawyers, drivers, teachers, chefs, and HR and marketing professionals under the Blue Arrow, Tate, Career Teacher, and Chadwick Nott brand names. The Healthcare segment provides healthcare workforce solutions, including healthcare staffing, managed services, staff bank, occupational health, insourcing, social care, and home care services under the Medacs Healthcare, Global Medics, and Litmus Workforce Solutions brand names. This segment also recruits locum, temporary and permanent doctors, nurses, care workers, and allied health professionals. The company was incorporated in 2008 and is based in Luton, the United Kingdom.
Full IGPPF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.